- Rexahn Pharmaceuticals Submits Archexin Phase II Protocol for Ovarian Cancer to FDA
May 8th, 2012 - Rexahn Pharmaceuticals Issued Japanese Patent for New Anti-cancer Compounds
April 30th, 2012 - Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-3117 at AACR 103rd Annual Meeting
March 27th, 2012 - Rexahn Pharmaceuticals Enrolls First Subject in Exploratory Phase I Clinical Study of RX-3117
March 13th, 2012 - Rexahn Pharmaceuticals Secures Approval in Europe to Conduct a First-in-Human Trial of RX-3117 in Solid Tumors
January 18th, 2012 - Rexahn Pharmaceuticals Provides Key Goals for 2012
January 17th, 2012 - Rexahn Pharmaceuticals Announces Phase II Results for Serdaxin as Treatment for Major Depressive Disorder
November 4th, 2011 - Rexahn Pharmaceuticals Granted US Patent for Novel Anti-cancer Isoquinolinamine Compounds
October 12th, 2011 - Rexahn Pharmaceuticals Announces Publication of Study Validating Mechanism of Action of Serdaxin
October 3rd, 2011 - Rexahn Pharmaceuticals Completes Patient Enrollment for Archexin Phase II Clinical Trial in Metastatic Pancreatic Cancer
September 28th, 2011
2012 - 2011 - 2010 - 2009 - 2008 - 2007 - 2006 - 2005 - 2004 - 2003